ArriVent BioPharma (AVBP) Income from Continuing Operations (2023 - 2026)
ArriVent BioPharma (AVBP) reported Income from Continuing Operations of 83371000.0 for Q1 2026, up 11.22% on a YoY basis from 74957515.36 in Q1 2025, and down 133.45% sequentially from 35712000.0 in Q4 2025.
ArriVent BioPharma (AVBP) Income from Continuing Operations (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Income from Continuing Operations data on file, last reported at 83371000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 11.22% year-over-year to 83371000.0; the trailing twelve-month figure through Mar 2026 stood at 250951000.0 (down 7.6% YoY), and the FY2025 full-year result was 197983000.0, down 51.32% from the prior year.
- Income from Continuing Operations slipped to 83371000.0 in Q1 2026, from 35712000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 12172000.0 in Q1 2023 to a low of 93912000.0 in Q1 2025.
- A 4-year average of 49846230.77 and a median of 55003000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 68.04% in 2024, while the deepest fall reached 340.46% in 2024.
- Tracing AVBP's Income from Continuing Operations over 4 years: stood at 65315000.0 in 2023, then surged by 68.04% to 20872000.0 in 2024, then slumped by 71.1% to 35712000.0 in 2025, then tumbled by 133.45% to 83371000.0 in 2026.
- Business Quant data shows AVBP's Income from Continuing Operations at 83371000.0 in Q1 2026, 35712000.0 in Q4 2025, and 63453000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | -83.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83.37 Mn |
| Dec 31, 2025 | -35.71 Mn |
| Sep 30, 2025 | -63.45 Mn |
| Jun 30, 2025 | -68.42 Mn |
| Mar 31, 2025 | -93.91 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Sep 30, 2024 | -63.43 Mn |
| Jun 30, 2024 | -55.00 Mn |
| Mar 31, 2024 | -50.38 Mn |
| Dec 31, 2023 | -65.32 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -21.57 Mn |
| Mar 31, 2023 | -12.17 Mn |